Bank of Montreal
ABCL icon

Bank of Montreal’s AbCellera Biologics ABCL Stock Holding History

Bank of Montreal’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.79M Buy
482,799
+301,109
+166% +$1.47M ﹤0.01% 1473
2026
Q1 		$634K Buy
181,690
+35,331
+24% +$127K ﹤0.01% 2279
2025
Q4 		$501K Buy
146,359
+80,851
+123% +$361K ﹤0.01% 2312
2025
Q3 		$330K Sell
65,508
-4,581
-7% -$20.2K ﹤0.01% 2485
2025
Q2 		$240K Buy
70,089
+22,155
+46% +$55.1K ﹤0.01% 2699
2025
Q1 		$107K Sell
47,934
-3,513
-7% -$10.1K ﹤0.01% 2900
2024
Q4 		$151K Sell
51,447
-6,566
-11% -$18.3K ﹤0.01% 2845
2024
Q3 		$151K Buy
58,013
+16,354
+39% +$45.3K ﹤0.01% 3124
2024
Q2 		$124K Sell
41,659
-2,468
-6% -$9.34K ﹤0.01% 3174
2024
Q1 		$199K Buy
44,127
+12,684
+40% +$64.7K ﹤0.01% 3056
2023
Q4 		$187K Sell
31,443
-30,081
-49% -$139K ﹤0.01% 3161
2023
Q3 		$331K Sell
61,524
-2,918
-5% -$17.8K ﹤0.01% 2737
2023
Q2 		$489K Sell
64,442
-4,375
-6% -$29.9K ﹤0.01% 2618
2023
Q1 		$521K Buy
68,817
+5,380
+8% +$48.9K ﹤0.01% 2436
2022
Q4 		$644K Sell
63,437
-83,311
-57% -$962K ﹤0.01% 2455
2022
Q3 		$1.55K Sell
146,748
-190,902
-57% -$2.09M ﹤0.01% 1961
2022
Q2 		$3.47K Buy
337,650
+209,148
+163% +$1.77M ﹤0.01% 1610
2022
Q1 		$1.26M Buy
128,502
+25,528
+25% +$242K ﹤0.01% 2189
2021
Q4 		$1.5M Sell
102,974
-12,490
-11% -$190K ﹤0.01% 1743
2021
Q3 		$2.25M Buy
115,464
+42,974
+59% +$760K ﹤0.01% 2006
2021
Q2 		$1.54M Buy
72,490
+3,767
+5% +$104K ﹤0.01% 2215
2021
Q1 		$2.1M Buy
68,723
+62,279
+966% +$2.48M ﹤0.01% 1779
2020
Q4 		$236K Buy
+6,444
New +$295K ﹤0.01% 3136

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of Montreal's ABCL Position: Q2 2026 in Review

Bank of Montreal increased its AbCellera Biologics (ABCL) stake by 166% in Q2 2026, buying an estimated $1.47M and bringing the position to 482,799 shares worth $3.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

Bank of Montreal first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. 142 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Bank of Montreal held 482,799 shares of AbCellera Biologics worth $3.79M as of Q2 2026.
  • Bank of Montreal bought 301,109 AbCellera Biologics shares in Q2 2026, an estimated $1.47M.
  • AbCellera Biologics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #1473 holding.
  • Bank of Montreal first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.